Global Cancer Biomarkers Market - Growth, Trends and Forecasts 2017 - 2022

  • ID: 4387357
  • Report
  • Region: Global
  • 211 pages
  • Mordor Intelligence
1 of 3
The global biomarkers market was worth USD $ 13.16 billion in 2011 and it is expected to reach USD 30.2 billion by 2019 at a CAGR of 14.60%.

Biomarkers are chemical, physical or biological parameters which can be used to indicate disease states. Oncology biomarkers offers high speed, non invasive cancer diagnosis and believe to enhance cancer detection and screening.

Major driving factors for the market are streamlined drug delivery process, noninvasive technology, increased rates of survival. Increase boost in government and private funding for oncology also fuels the market growth. Market is constrained by high cost of diagnosis, issues related to reimbursement and some of the regulatory policies which hinder the market growth. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) have taken an active interest in the field.

Global biomarkers market is segmented based on type of applications, By services and based on Geography. Global Cancer Biomarker market is segmented based on Cancer biomarker discovery market , and cancer biomarker diagnostic market. Among the different regions of the world, North America is recorded as the leading biomarker marker due to rapid growth of IT industry and high adoption of throughput technologies, for the discovery of biomarkers.

Some of the major players in this market are Abbott Laboratories,Correlogic Systems, Inc, Agendia Bv,Biocurex Inc,Astellas Pharma Us Inc, Beckman Coulter, Inc, Becton, Dickinson And Company, Biomerieux S.A., Biomoda, Inc, Clarient, Inc, Ambrilia Biopharma,Diadexus, Inc, Affymetrix, Inc and Aureon Laboratories, Inc. .

What makes our report Unique?

1) A wide and in depth analysis of various applications, and services provided in Global Biomarker market as well as cancer biomarker market.

2) We provide longest possible market segmentation based on the type of cancers, applications of biomarkers( Risk assessment, disease diagnosis, drug formulation, forensic application) Services( Sample preparation, Assay development, biomarkers validation and testing)

3) We provide you a complete competitive landscape which includes major players in the market, mergers and acquisitions, Collaborations and new product launches.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study Deliverables
1.2 Market Definition
1.3 Sizing Units
1.4 Base Currency
1.5 Review and Forecast Period Years
1.6 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Analysis Methodology
2.3 Econometric Forecast Model
2.4 Research Assumptions
3. Executive Summary
4. Key Inferences
5. Market Overview and Industry Trends
5.1 Current Market Scenario
5.2 Applications of Cancer Biomarkers
5.3 Technology Overview
5.4 New Developments
5.5 Industry Value-Chain Analysis
5.6 Product Life-Cycle Analysis
5.7 Product Benchmarking
5.8 Investment Analysis
5.9 Porter’s Five Forces
5.9.1 Bargaining Power of Suppliers
5.9.2 Bargaining Power of Consumers
5.9.3 Threat of New Entrants
5.9.4 Threat of Substitute Products and Services
5.9.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
7. Market Drivers
7.1 Non invasive technologies
7.2 Increased survival rates
7.3 Enhanced accuracy and Speed of diagnosis
7.4 Streamlined drug delivery process
7.5 Helps in FDA approval of drugs
7.6 Boost in government and Private funds for biomarkers discovery
8. Market Restraints
8.1 High cost of diagnosis
8.2 Reimbursement issues
8.3 Need for immediate processing
9. Key Challenges
9.1 Discovery of novel biomarkers
9.2 Regulatory and Reimbursement issues
9.3 Translational genetics
10. Current Opportunities in the Market
10.1 Genetics-based in-vitro diagnostics
10.2 Research and development
11. Market Segmentation
11.1 By Disease
11.1.1 Prostate cancer
11.1.2 Breast cancer
11.1.3 Lung cancer
11.1.4 Colorectal cancer
11.1.5 Cervical Cancer
11.1.6 Others
11.2 By Applications
11.2.1 Risk Assesment
11.2.2 Devlopment of molecular diagnostics
11.2.3 Disese diagnosis
11.2.4 Drug discovery and development
11.2.5 Drug formulation
11.3 By Services
11.3.1 Sample preparation
11.3.2 Assay developement
11.3.3 Biomakers validation and testing
11.4 By Type
11.4.1 Protein biomarkers
11.4.2 Genetic biomarkers
11.4.3 Others (Cell, Viral and Carbohydrate biomarkers)
11.5 By profiling technologies
11.5.1 Omics technologies Genomics Proteomics Metabolomics Transcriptomics Pharmacogenomics
11.5.2 Imaging technologies
11.5.3 Immunoassays Immunohistochemical (IHC) tests Flow cytometry
11.5.4 Cytogenetics DNA microarrays
11.5.5 Bioinformatics
11.5.6 IVD multivariate index assays
11.6 By Geography
11.6.1 North America Introduction US Canada Mexico
11.6.2 Europe Introduction France UK Germany Russia Italy Spain & Portugal Scandinavia BENELUX
11.6.3 Asia-Pacific Introduction India China Japan Australia & New Zealand Soth Korea
11.6.4 Middle-East and North Africa (MENA) Introduction GCC Egypt Sudan Morocco
11.6.5 South America Introduction Brazil Argentina Colombia Chile Peru Venezuela
12. Competitive Landscape
12.1 Merger and Acquisition Analysis
12.2 New Product Launches
12.3 Agreements, Collaborations & Partnerships
13. 9. Company Profiles
13.1 Abbott Laboratories
13.2 Affymetrix Inc
13.3 Agilent Technologies
13.4 Gen-Probe Inc
13.5 Hologic Inc
13.6 Roche Diagnostics Corp.
13.7 23andMe
13.8 Ambry Genetics
13.9 Astex Pharmaceuticals
13.10 Atossa Genetics
13.11 BioMerieux
13.12 CuraGen
13.13 Celera Corporation (Quest Diagnostics)
13.14 Celldex Therapeutics
13.15 deCode Genetics (Amgen)
13.16 Foundation Medicine
13.17 Illumina
13.18 Genelex
14. Analyst Outlook for Investment Opportunities
15. Future Outlook of the Market
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown